Scientists are developing the next generation of chips bioreactor to produce functional human platelets -
Scientists from Brigham and Hospital (BWH) of the women developed a scalable, the next generation of platelets bioreactor to produce fully functional human platelets in vitro. The work is a major biomedical breakthrough that will contribute to the blood transfusion needs to address worldwide.
The study is published July 21, 2014 Blood .
"The ability to generate another source of functional human platelets with virtually no transmission of the disease represents a paradigm shift in how we collect platelets that can enable us to meet the needs of increasingly for blood transfusions, "said Jonathan Thon, PhD, Division of Hematology, Department of medicine at BWH, lead author of the study.
According to the researchers, more than 2.17 million units platelets from donors are transfused each year in the United States to treat patients undergoing chemotherapy, organ transplantation and surgery, and for those who need blood transfusions following a major trauma. However, growing demand, a limited life span of five days. and the risk of infection, rejection and infection were shortages of common blood platelets
"derived platelets bioreactor theoretically have several advantages over conventional platelet donors derivatives in terms of security and the use of resources, "said William Savage, MD, PhD, medical Director, blood donor Centre Kraft family at Dana-Farber Cancer Institute / Brigham and Women's Hospital, which has not contributed to the study. "An important factor that has limited our ability to compare platelet bioreactor platelet donors is inefficient increasingly wafers, a problem that slows the progress of clinical research. This study addresses this gap, while contributing to our understanding of the biology of platelets at the same time. "
blood cells such as platelets are made in the bone marrow. bioreactor-a the device that mimics a biological environment to carry a reaction on an industrial scale biologically inspired engineering applications to fully integrate the key components of the bone marrow, the modeling of both characteristics and composition of the blood. the microfluidic bioreactor wafer summarizes the characteristics such as stiffness bone marrow, the composition of the extracellular matrix, the size of microchannels, and the stability of blood flow in high-resolution microscopy of living cells to human platelets.
Application of shear forces of blood flow in the bioreactor triggered a dramatic increase in the initiation of platelet 10 percent to 0 percent, which leads to functional human platelets.
"being able to develop a device that models of successful bone marrow is an essential bridge between our understanding of physiological triggers platelet formation to support drug development and production of platelets large scale, "said study senior author Joseph Italiano, Jr., Ph.D., Division of Hematology, Department of medicine at BWH, and vascular biology Program at Boston children's Hospital.
regarding the next steps, the researchers would like to start Phase 0 / I in human clinical trials in 2017.
"the regulatory bar is set correctly for high blood products, and it is important to that we show platelet quality, function and safety over the next three years as we are likely to be recipients of these platelets ourselves at some point, "said Thon.
EmoticonEmoticon